Analysts Set Altimmune, Inc. (NASDAQ:ALT) Target Price at $20.83

Altimmune, Inc. (NASDAQ:ALT) has been given an average recommendation of “Moderate Buy” by the nine analysts that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $20.83.

ALT has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Altimmune in a research note on Wednesday, February 5th. UBS Group initiated coverage on Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target on the stock. Stifel Nicolaus began coverage on Altimmune in a research note on Wednesday, January 8th. They set a “buy” rating and a $18.00 price target on the stock. Finally, William Blair began coverage on Altimmune in a research report on Friday. They set a “market perform” rating for the company.

Altimmune Stock Performance

Shares of NASDAQ ALT opened at $6.65 on Wednesday. The stock’s fifty day moving average is $6.85 and its 200 day moving average is $7.19. The stock has a market capitalization of $472.95 million, a P/E ratio of -4.29 and a beta of 0.19. Altimmune has a 52 week low of $5.28 and a 52 week high of $14.05.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. Equities research analysts forecast that Altimmune will post -1.35 earnings per share for the current year.

Institutional Investors Weigh In On Altimmune

A number of hedge funds have recently added to or reduced their stakes in ALT. Larson Financial Group LLC bought a new stake in Altimmune in the third quarter worth approximately $31,000. SBI Securities Co. Ltd. bought a new stake in Altimmune in the fourth quarter worth approximately $45,000. Virtus ETF Advisers LLC bought a new stake in Altimmune in the fourth quarter worth approximately $60,000. Cullen Frost Bankers Inc. bought a new stake in Altimmune in the fourth quarter worth approximately $72,000. Finally, 180 Wealth Advisors LLC bought a new stake in Altimmune in the fourth quarter worth approximately $78,000. 78.05% of the stock is currently owned by institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.